Table 3.
Safety profile of the 79 elderly patients with ES-SCLC who received anlotinib treatment
| Adverse Reactions | Total (N, %) | Grade 1–2 (N, %) | Grade ≥3 (N, %) |
|---|---|---|---|
| Hypertension | 32 (40.5) | 23 (29.1) | 9 (11.4) |
| Hand-foot syndrome | 25 (31.6) | 20 (25.3) | 5 (6.3) |
| Diarrhea | 22 (27.8) | 20 (25.3) | 2 (2.5) |
| Decreased appetite | 16 (20.3) | 16 (20.3) | 0 (0.0) |
| Fatigue | 14 (17.7) | 11 (13.9) | 3 (3.8) |
| Weight loss | 14 (17.7) | 14 (17.7) | 0 (0.0) |
| Hematological toxicity | 11 (13.9) | 9 (11.4) | 2 (2.5) |
| Hypertriglyceridemia | 9 (11.4) | 9 (11.4) | 0 (0.0) |
| AST/ALT elevation | 7 (8.9) | 6 (7.6) | 1 (1.3) |
| Dizziness | 5 (6.3) | 5 (6.3) | 0 (0.0) |
| Hemoptysis | 2 (2.5) | 2 (2.5) | 0 (0.0) |
Abbreviations: ES-SCLC, extensive-stage small cell lung cancer; AST, aspartate amino transferase; ALT, alanine aminotransferase.